Core Viewpoint - In 2024, Xingqi Eye Medicine (300573.SZ) demonstrated strong growth in the ophthalmic prescription drug sector, achieving significant revenue and profit increases, solidifying its leading position in the industry [1][2]. Financial Performance - The company reported a total revenue of 1.943 billion yuan in 2024, representing a year-on-year increase of 32.42% [2]. - Net profit reached 338 million yuan, up 40.84% year-on-year, with a non-recurring net profit growth of 44.54% to 348 million yuan [2]. - The net cash flow from operating activities was 417 million yuan, reflecting a 31.31% increase [2]. Product Performance - The eye drop segment showed remarkable growth, generating 1.366 billion yuan in revenue, a 106.08% increase, and accounting for 70.3% of total revenue [2]. - Key products driving this growth included low-concentration atropine eye drops (brand name "Mei Ou Pin") and cyclosporine eye drops (II) [2]. Investor Returns - The company proposed a profit distribution plan, intending to distribute a cash dividend of 10 yuan per 10 shares, totaling 175 million yuan, and a capital reserve conversion of 4 shares for every 10 shares held [3]. Production and Quality Management - The company focused on enhancing production and quality management, optimizing resource allocation, and upgrading production facilities to improve efficiency and support smart factory initiatives [4]. - Quality management improvements included passing various regulatory inspections and certifications, indicating a stable and effective quality management system [5]. Research and Development - In 2024, R&D expenses reached 221 million yuan, a 31.90% increase, with the company holding 66 invention patents [6]. - Significant progress was made in R&D, including the approval of clinical trials for new products aimed at treating common eye diseases [6][7]. Future Outlook - For 2025, the company reported a revenue of 536 million yuan in Q1, a 53.24% increase, and a net profit of 146 million yuan, up 319.86% year-on-year [8]. - The company outlined four key operational plans for 2025: production and quality centers, product R&D, marketing, and internal control management, with a focus on unmet clinical needs and innovation [9].

Group 1 - The company plans to distribute a cash dividend of 10 yuan per 10 shares and a capital reserve conversion of 4 shares for every 10 shares at the end of 2024, totaling a dividend payout of 175 million yuan [1] - The total dividend distribution for 2024, including the mid-year payout of 87.21 million yuan, amounts to 262 million yuan, representing 77.64% of the net profit attributable to shareholders [1] - The company has conducted a total of 9 year-end dividends and 4 mid-year dividends since its listing in 2016, with a cumulative dividend amount of 999.5 million yuan and an average dividend rate of 81.82% [5] Group 2 - The company specializes in the field of ophthalmic drugs, with 60 approved ophthalmic drug numbers, of which 38 are included in the medical insurance catalog and 6 in the national essential drug catalog [4] - In 2024, the company achieved significant growth, with operating revenue of 1.943 billion yuan, a year-on-year increase of 32.42%, and a net profit of 338 million yuan, a year-on-year increase of 40.84% [4] - The company’s net cash flow from operating activities reached 417 million yuan, reflecting a year-on-year growth of 31.31% [4]

更适合长期治疗的慢性反复发作患者。 本文为IPO早知道原创 作者｜C叔 微信公众号｜ipozaozhidao 据IPO早知道消息，2月25日，兆科眼科（6622.HK）宣布其全资附属子公司兆科（广州）眼科药物 有限公司，与浙江视方极医药科技有限公司（下称"视方极"）联合发布国内首款单剂量不含抑菌剂 的盐酸氮䓬斯汀滴眼液产品（顺敏®），为过敏性结膜炎患者提供更全面的治疗方案选择。 近年来，中国国内过敏性结膜炎的发病率逐年上升，预计到2030年，全国过敏性结膜炎患者将超过 3亿人。盐酸氮䓬斯汀滴眼液的推出有望为广大过敏性结膜炎患者带来新的希望，3分钟迅速起效， 持续时间长达10小时。0.4毫升单支装不添加抑菌剂，更适合长期治疗的慢性反复发作患者。该产品 的成功上市不仅有助于进一步满足临床用药需求，也为过敏性结膜炎患者提供了优质的治疗方式。 此次兆科眼科和视方极的联手合作是双方在眼科药物领域发展的重要里程碑。结合兆科眼科的商业化 实力及视方极的产品研发优势，双方加强互补合作，旨在为中国眼科治疗领域落实更多的创新成果， 为患者提供更安全更高效的解决方案。 视方极为国内创新型医药企业，2021年成立于浙江杭州，已构建眼 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本集團獲得治療乾眼症的全球首創創新產品的獨家開發及商業化權益 本公告乃遠大醫藥集團有限公司(「本公司」，連同其附屬公司統稱「本集團」)之董事 會(「董事會」)自願刊發。 董事會欣然公告，近日，本集團與箕星藥業香港有限公司(「箕星」)達成產品引進戰略 合作協議。根據協議，在相關條件滿足後，本集團將獲得用於治療乾眼症的全球首創創 新產品酒石酸伐尼克蘭鼻噴霧劑「( OC-01」)及 OC-02（Simpinicline）鼻噴霧劑「( OC-02」) 在大中華區（中國大陸、中國香港特別行政區、中國澳門特別行政區、台灣地區）的獨 家開發及商業化權益。此次戰略合作將進一步深化本集團在眼科領域的創新產品佈局。 箕星是一家總部位於美國和中國的生物科技公司，致力於將創新科學和藥物帶給罹患嚴 重危及生命健康的全球患者，其重磅產品 OC-01 和 OC-02 是兩種高選擇性的乙醯膽鹼 能受體激動劑，可通過啟動三叉神經副交感神經 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Grand Pharmaceutical Group Limited 遠大醫藥集團有限公司* ( 於百慕大註冊成立之有限公司 ) （股份代號：00512） 自願性公告 本集團全球創新眼科藥物 GPN00833 完成國內ⅠⅠⅠ期臨床研究並達到了臨床終點 本公告乃遠大醫藥集團有限公司(「本公司」，連同其附屬公司統稱「本集團」)之董事 會(「董事會」)自願刊發。 董事會欣然公告，近日，本集團用於眼科術後抗炎鎮痛的激素納米混懸滴眼液 GPN00833 完成了在中國開展的 III 期臨床研究並成功達到了臨床終點，是本集團在五官科領域眼 科方向的又一次重大里程碑進展。 GPN00833 為抗炎鎮痛類激素納米混懸滴眼液，其主要活性成分丙酸氯倍他索是一種強 效的糖皮質激素，具有高效的局部抗炎活性和較強的毛細血管收縮作用，同時其獨特的 納米製劑工藝有效解決了激素產品低水溶性導致的生物利用度低及安全性風險。該產品 於二零二三 ...